NASDAQ:LVTX LAVA Therapeutics (LVTX) Stock Price, News & Analysis → The #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique Way (From Smallcaps Daily) (Ad) Free LVTX Stock Alerts $3.08 +0.08 (+2.67%) (As of 05/8/2024 ET) Add Compare Share Share Today's Range$2.92▼$3.1450-Day Range$2.16▼$4.0352-Week Range$1.13▼$6.47Volume35,889 shsAverage Volume1.31 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get LAVA Therapeutics alerts: Email Address LAVA Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside94.8% Upside$6.00 Price TargetShort InterestHealthy1.37% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.41) to ($1.77) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.85 out of 5 stars 3.5 Analyst's Opinion Consensus RatingLAVA Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLAVA Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about LAVA Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.37% of the float of LAVA Therapeutics has been sold short.Short Interest Ratio / Days to CoverLAVA Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in LAVA Therapeutics has recently decreased by 8.41%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldLAVA Therapeutics does not currently pay a dividend.Dividend GrowthLAVA Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LVTX. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for LAVA Therapeutics this week, compared to 0 articles on an average week.Search InterestOnly 10 people have searched for LVTX on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.MarketBeat Follows3 people have added LAVA Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, LAVA Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.79% of the stock of LAVA Therapeutics is held by insiders.Read more about LAVA Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for LAVA Therapeutics are expected to decrease in the coming year, from ($1.41) to ($1.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of LAVA Therapeutics is -1.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of LAVA Therapeutics is -1.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLAVA Therapeutics has a P/B Ratio of 0.91. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about LAVA Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsFidelity, Bezos, Goldman Bet Big on Tiny BiotechAre you ready for a major shift in the investment world? There's a new drug The Wall Street Journal is calling the "King Kong" of drugs.Don't miss out on the "next Ozempic" >>> About LAVA Therapeutics Stock (NASDAQ:LVTX)LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.Read More LVTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LVTX Stock News HeadlinesMay 6, 2024 | globenewswire.comLAVA Therapeutics to Participate in the Citizens JMP Life Sciences ConferenceMay 4, 2024 | americanbankingnews.comLAVA Therapeutics (NASDAQ:LVTX) Trading Down 2.3%May 8, 2024 | Banyan Hill Publishing (Ad)READ THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”March 25, 2024 | markets.businessinsider.comBuy Rating Affirmed for LAVA Therapeutics Amid Promising T-Cell Cancer Therapy Trials and Strong FinancialsMarch 20, 2024 | finance.yahoo.comLAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial ResultsMarch 20, 2024 | globenewswire.comLAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial ResultsMarch 6, 2024 | finanznachrichten.deLAVA Therapeutics N.V.: LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)March 5, 2024 | msn.comLava gets $7M from Pfizer as trial for cancer drug advancesMay 8, 2024 | Banyan Hill Publishing (Ad)READ THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”March 5, 2024 | globenewswire.comLAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)March 1, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: AdaptHealth (AHCO), LAVA Therapeutics (LVTX)February 21, 2024 | benzinga.comLAVA Therapeutics Stock (NASDAQ:LVTX), Short Interest ReportFebruary 14, 2024 | investing.comLAVA Therapeutics NV (LVTX)January 25, 2024 | msn.comLava signs collaboration agreement with MSD for prostate cancer therapyJanuary 25, 2024 | seekingalpha.comPCSA, ONCO and KAVL among mid-day moversJanuary 25, 2024 | finance.yahoo.comLAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®December 13, 2023 | ca.finance.yahoo.comLAVA Therapeutics N.V. (LVTX)November 11, 2023 | morningstar.comLAVA Therapeutics NV LVTXAugust 25, 2023 | bizjournals.comLava Therapeutics is latest life sciences company to trim its workforceAugust 22, 2023 | finanznachrichten.deLAVA Therapeutics N.V.: LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial ResultsAugust 22, 2023 | finance.yahoo.comLAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial ResultsJuly 6, 2023 | msn.comLAVA Therapeutics (LVTX) Price Target Decreased by 44.62% to 7.34June 14, 2023 | finanznachrichten.deLAVA Therapeutics N.V.: LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash RunwayJune 14, 2023 | msn.comLava Therapeutics shelves hematology drug over competitive concernsJune 12, 2023 | msn.comHC Wainwright & Co. Reiterates LAVA Therapeutics (LVTX) Buy RecommendationJune 9, 2023 | markets.businessinsider.comJMP Securities Remains a Buy on LAVA Therapeutics (LVTX)June 1, 2023 | finance.yahoo.comLAVA Therapeutics to Participate in the Jefferies Healthcare ConferenceSee More Headlines Receive LVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LAVA Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/20/2024Today5/08/2024Next Earnings (Estimated)6/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LVTX CUSIPN/A CIK1840748 Webwww.lavatherapeutics.com Phone31-85-016-3100FaxN/AEmployees37Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+99.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,970,000.00 Net Margins-620.09% Pretax Margin-615.97% Return on Equity-68.54% Return on Assets-35.68% Debt Debt-to-Equity Ratio0.01 Current Ratio6.62 Quick Ratio6.62 Sales & Book Value Annual Sales$6.77 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.39 per share Price / Book0.89Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable Beta0.69 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Stephen Allen Hurly M.B.A. (Age 56)M.Sc., CEO, President & Executive Director Mr. Fred M. Powell CPA (Age 63)Chief Financial Officer Dr. Hans van der Vliet M.D. (Age 50)Ph.D., Chief Scientific Officer Ms. Amy Garabedian J.D. (Age 48)General Counsel & Corporate Secretary Mr. Wouter van HunnikVP & Head of Human ResourcesDr. Ton Adang Ph.D. (Age 63)Chief Development Officer Dr. Charles Q. Morris M.D. (Age 59)MBChB, MRCP (UK), Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsContext TherapeuticsNASDAQ:CNTXGrifolsNASDAQ:GRFSMainz BiomedNASDAQ:MYNZNLS PharmaceuticsNASDAQ:NLSPPharvarisNASDAQ:PHVSView All CompetitorsInstitutional OwnershipPathway Financial Advisors LLCBought 14,000 shares on 4/10/2024Ownership: 0.000%View All Institutional Transactions LVTX Stock Analysis - Frequently Asked Questions Should I buy or sell LAVA Therapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LAVA Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LVTX shares. View LVTX analyst ratings or view top-rated stocks. What is LAVA Therapeutics' stock price target for 2024? 2 Wall Street analysts have issued 12 month price objectives for LAVA Therapeutics' shares. Their LVTX share price targets range from $6.00 to $6.00. On average, they predict the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 94.8% from the stock's current price. View analysts price targets for LVTX or view top-rated stocks among Wall Street analysts. How have LVTX shares performed in 2024? LAVA Therapeutics' stock was trading at $1.58 at the beginning of 2024. Since then, LVTX stock has increased by 94.9% and is now trading at $3.08. View the best growth stocks for 2024 here. Are investors shorting LAVA Therapeutics? LAVA Therapeutics saw a decrease in short interest in March. As of March 31st, there was short interest totaling 211,600 shares, a decrease of 34.3% from the March 15th total of 322,100 shares. Based on an average trading volume of 1,750,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 1.5% of the company's shares are short sold. View LAVA Therapeutics' Short Interest. When is LAVA Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, June 13th 2024. View our LVTX earnings forecast. How were LAVA Therapeutics' earnings last quarter? LAVA Therapeutics (NASDAQ:LVTX) announced its earnings results on Wednesday, March, 20th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.16 by $0.40. The firm had revenue of $0.35 million for the quarter, compared to the consensus estimate of $25 million. LAVA Therapeutics had a negative net margin of 620.09% and a negative trailing twelve-month return on equity of 68.54%. When did LAVA Therapeutics IPO? LAVA Therapeutics (LVTX) raised $100 million in an initial public offering on Thursday, March 25th 2021. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and SVB Leerink served as the underwriters for the IPO and Kempen & Co. was co-manager. Who are LAVA Therapeutics' major shareholders? LAVA Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Pathway Financial Advisors LLC (0.00%). How do I buy shares of LAVA Therapeutics? Shares of LVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LVTX) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyElon Musk Secret Crypto Plot ExposedCrypto 101 MediaAI “wealth window” is closing June 25thParadigm PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward PressThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LAVA Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
